Literature DB >> 9643276

Limitation of left ventricular hypertrophy and dysfunction by ACE inhibition after anterior Q-wave myocardial infarction.

B I Jugdutt1, D P Humen.   

Abstract

To determine whether limitation of left ventricular (LV) hypertrophy with angiotensin-converting enzyme inhibition after myocardial infarction (MI) is associated with improved systolic and diastolic function, quantitative two-dimensional echocardiograms and Doppler of 40 patients, who were randomized on day 3 after a first Q-wave anterior MI to receive therapy with captopril (12.5 mg t.i.d.) or placebo for 6 weeks, were analyzed for LV volumes (Simpson's rule) and mass (3D reconstruction), remodeling parameters and peak early (E) and late (A) transmitral flow velocities and deceleration times (DT) at 3 days, 6 weeks, 6 months and 1 year. Compared to placebo over 1 year, captopril limited (p < 0.001) the increase in diastolic volume and mass, increased LV ejection fraction and diastolic E/A ratio, and decreased DT, the frequency of E and A reversal, infarct expansion and aneurysm frequency but volume/ mass ratio was unchanged. Captopril over the first 6 weeks after a first Q-wave anterior MI limited LV remodeling and hypertrophy and improved both systolic and diastolic function up to 1 year.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9643276     DOI: 10.1159/000006801

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  3 in total

Review 1.  Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2008-02-07       Impact factor: 4.214

Review 2.  Nitric oxide and cardioprotection during ischemia-reperfusion.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

3.  Mechanisms of Post-Infarct Left Ventricular Remodeling.

Authors:  Brent A French; Christopher M Kramer
Journal:  Drug Discov Today Dis Mech       Date:  2007
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.